Tarextumab ELISA Kit (DC513018)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DC513018
Description	Tarextumab ELISA Kit (DC513018) — Quantitative sandwich ELISA for Tarextumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Sensibilité	0.156 μg/ml
Plage	0.31-5 μg/mL
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	NOTCH2
Noms alternatifs	OMP-59R5, 1359940-55-8
Contexte	Tarextumab, is a fully human mAb that inhibits ligand-dependent signaling through both Notch2 and Notch3. Tarextumab was tested in a range of xenograft models and found to be active in breast, ovarian, lung, and pancreatic tumors. Administration of tarextumab delayed tumor recurrence after chemotherapeutic treatment and reduced tumor-initiating cell frequency, particularly in combination with chemotherapy. Mechanism of action studies indicated that tarextumab blocked Notch signaling in both tumor and stromal cells and induced differentiation of tumor cells. In the stromal cells, tarextumab inhibited gene expression required for the function of pericytes, vascular support cells essential for tumor angiogenesis.
Note	For Research Use Only.